Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio.
| Website: | www.amicusrx.com |
| Email: | ir@amicusrx.com |
| Main Phone: | +1 215 921-7600 |
| Address: | 3675 Market Street |
| State: | PA |
| City / Town: | Philadelphia |
| Country: | US |
| Postal Code: | 19104 |
| Exchange: | NSD |
| CEO: | John F. Crowley |
| Employees: | 483 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
After missing earlier this month on achieving a statistically significant response in a phase 3 study with partner GlaxoSmithKline (GSK) for migalastat HCl against Fabry disease that chopped their
Initial Jobless Claims were higher than expected in the latest week at 428,000. Remember that the Recessionary Threshold is 350,000. The Chicago PMI rose to a stronger than expected reading of
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 22 | 110 |
| Number of Buys | 13 | 61 |
| Number of Sells | 9 | 49 |
| Net Activity | -78433 | 2199222 |
| Last 10 Buys | Shares |
|---|---|
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Ellen S. Rosenberg | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Hung Do | 1,000 |
| Hung Do | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Jay Barth | 1,000 |
| Hung Do | 1,000 |
| Michael G. Raab | 1,000 |
| Jay Barth | 1,000 |
| Kurt J. Andrews | 1,000 |
| William D. Baird | 1,000 |
| Jay Barth | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 22 | 22 | 22 | 22 |
| Low Target Price Estimate | 18.5 | 18.5 | 18.5 | 18.5 |
| Mean Target Price Estimate | 20.08 | 20.08 | 20.08 | 20.08 |
| Standard Deviation | 1.56 | 1.56 | 1.56 | 1.56 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 21 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
